Skip to content
Ransomware

RansomHub ransomware group lists www.fibrogen.com on its leak site

The RansomHub ransomware group has listed www.fibrogen.com, an entity operating in the healthcare sector, on its leak site.

By
Siberpol Intelligence Unit
Published
3 min read
3 min read
  • Ransomware group: RansomHub
  • Country: United States
  • Sector: Healthcare
  • Announcement date: December 3, 2024

RansomHub claims to have targeted FibroGen

The RansomHub ransomware group has officially listed the organization www.fibrogen.com on its dedicated leak site. This announcement, which surfaced on December 3, 2024, marks a potential data breach involving an entity operating within the healthcare sector.

Ransomware groups often utilize leak sites to exert pressure on their victims through a tactic known as double extortion. In such scenarios, threat actors do not only encrypt an organization's systems to disrupt operations but also steal sensitive information. The threat of leaking this data on a public forum serves as a powerful lever to coerce the victim into paying a ransom. While the listing is a claim made by the threat actor, it highlights the ongoing risks faced by specialized industries.

Details of the alleged attack

According to the post published by the threat actor, the breach is linked to unauthorized access obtained on November 19, 2024. The RansomHub group alleges that they successfully gained access to the organization's network and subsequently acquired data from the entity. This timeline suggests that the attackers may have maintained presence within the network for a period before making their public announcement.

Ransomware-as-a-Service (RaaS) models, such as the one operated by RansomHub, allow developers to lease their malicious software to various affiliates. This modular approach enables different actors to carry out attacks using the same infrastructure. RansomHub notably emerged in early 2024 and reportedly absorbed several affiliates from the ALPHV group. Although reports indicate the group may have ceased operations in early 2025, their historical activities continue to impact the cybersecurity landscape.

Information regarding the leaked data

At this stage, there is no information available regarding the specific nature of the leaked or compromised data. The announcement does not specify the types of files, the volume of information, or the total size of the data acquired during the intrusion. Furthermore, no ransom demand has been publicly disclosed in relation to this specific listing.

The listing names no data types.

Attempts to verify the contents of the leak via the group's platform have been unsuccessful, as the provided screenshot indicates the leak site is currently inaccessible, displaying an error page. This lack of accessibility is common in many cybercrime operations, whether due to law enforcement intervention, technical failures, or the group's own operational shifts.

About FibroGen

FibroGen is a biopharmaceutical company that develops innovative medicines for the treatment of serious diseases such as fibrosis, cancer, and anemia. The company focuses on clinical-stage therapies, particularly in the fields of tissue repair and regenerative medicine.

Risk assessment and industry implications

This incident suggests a potential risk of exposure for sensitive data within the healthcare sector. For organizations in this industry, a successful data breach can lead to significant legal consequences under strict regulatory frameworks, such as the Health Insurance Portability and Accountability Act (HIPAA). Such regulations are designed to ensure the privacy and security of protected health information.

Beyond the immediate legal and regulatory challenges, the publication of sensitive data can lead to secondary risks for both employees and patients. These risks include the possibility of identity theft or the execution of highly targeted phishing attacks. When personal or medical information is exposed, it becomes a valuable commodity for other malicious actors looking to conduct social engineering attacks.

To mitigate these risks, organizations in the healthcare and biopharmaceutical sectors typically focus on robust defensive measures. This includes implementing multi-factor authentication, maintaining rigorous patch management protocols, and conducting regular network monitoring to detect unauthorized access. Additionally, maintaining offline backups and conducting comprehensive incident response drills are essential components of a modern cybersecurity posture designed to defend against the evolving tactics of RaaS groups.

In the Intelligence 360 plan

Attack Surface Management

See the assets tied to your domains, the technologies they run and known vulnerabilities in one list.

Related stories